ecancer

ecancer.org

ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.

 

ecancer
S

ESMO 2022 Results From a Phase 3 Study of 1L Atezo vs. Single-Agent Chemo in Pts With NSCLC

By ecancer FEATURING Siow Ming Lee
By ecancer FEATURING Siow Ming Lee
12 views
September 27, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

08:44
Johnson & Johnson

Management and Proactive Care of Adverse Events Associated with Loca…

Feat. J. Sabari, A. Spira

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy
ESMO 2022
33:28

ESMO 2022: Highlights, Commentary, and Analysis of the Key Studies

ecancer

B. Gyawali

490 views
04:14

ESMO 2022 Phase III SOLO1/GOG-3004 Trial: Maintenance Olaparib Conti…

ecancer

P. DiSilvestro

132 views
06:05

ESMO 2022 Open-Label Phase 3 Trial: Treatment With Tumour-Infiltrati…

ecancer

J. Haanen

70 views
25:25

ESMO 2022 Updates in Prostate Cancer

ecancer

E. Efstathiou, B. Hadaschik, G. Attard

257 views
20:47

ESMO 2022 on the Latest in mRCC

ecancer

J. Puente, B. Escudier, V. Grünwald, S. Oudard

195 views
06:50

ESMO 2022 Updates in Renal Cancer

ecancer

T. Choueiri

292 views
22:01

ESMO 2022 on the Latest in PARP Inhibitors for Metastatic Prostate C…

ecancer

N. Shore, P. Rescigno, N. Clarke, F. Schlürmann

81 views
04:22

ESMO 2022 on the COSMIC-313 Phase 3 Study: Cabozantinib in Combinati…

ecancer

T. Choueiri

228 views
05:32

ESMO 2022 on the Phase III DeFi Trial: Nirogacestat Demonstrates Cli…

ecancer

B. Kasper

50 views
09:06

ESMO 2022 on the Phase 3 KEYNOTE-412 Study: Pembro With CRT vs. Plac…

ecancer

J. Machiels

60 views
06:44

ESMO 2022 on the New Data for Multi-Cancer Early Detection

ecancer

T. Beer

64 views
09:48

ESMO 2022 on the PATHFINDER Study: A New Era of Early Cancer Detecti…

ecancer

D. Schrag

1.1K views
03:12

ESMO 2022 on the Phase 3 RATIONALE-301 Study: Tislelizumab OS Benefi…

ecancer

R. Finn

37 views
05:19

ESMO 2022 on the Phase 3 LEAP-002 Study: Lenvatinib Remains Standard…

ecancer

R. Finn

50 views
03:33

ESMO 2022: Fruquintinib Provides Improvement in Overall Survival for…

ecancer

A. Dasari

16 views
04:32

ESMO 2022 on mBC Endpoints for Survival: rwPFS and TTNT

ecancer

C. Labaki

29 views
04:34

ESMO 2022 on the ELAINE Trial: Lasofoxifene vs. Fulvestrant for Loca…

ecancer

M. Goetz

176 views
10:37

ESMO 2022 Breast Cancer Highlights

ecancer

M. Lambertini

626 views
04:19

ESMO 2022 on MONARCH 3 Interim Data: Abemaciclib + NSAI for HR+, HER…

ecancer

M. Goetz

182 views
05:36

ESMO 2022 on the Phase 3 CodeBreaK 200 Trial: Sotorasib Demonstrates…

ecancer

M. Johnson

161 views
06:35

ESMO 2022 PEACE Study: Scientists Discover Mechanism of Action and a…

ecancer

C. Swanton

87 views
05:10

ESMO 2022 Results From a Phase 3 Study of 1L Atezo vs. Single-Agent …

ecancer

S. Lee

12 views
20:28

ESMO 2022 on EGFR Mutations in NSCLC: From Biomarker to Treatment Se…

ecancer

N. Girard, K. Kerr, A. Addeo, J. Reuss

294 views
05:19

ESMO 2022: Atezolizumab Improves on Single-Agent Chemo for NSCLC Not…

ecancer

S. Lee

135 views